Analysis of the overall survival of patients with varying immunoreactivities of tumor tissues for IL6 expression.

(A) Kaplan-Meier survival curves for OSCC patients who were classified with either low/negative (weak (1+) or negative (−) IHC positivity) or high IL6 (strong (3+) or moderate (2+) IHC positivity) expression. The IL6 status was not significantly associated (log-rank, P = 0.134) with patient survival. (B) In male OSCC patients, the IL6 status was significantly associated (log-rank, P = 0.014) with patient survival. (C) In female OSCC patients, no significant association was found for IL6 expression and patient survival (log-rank, P = 0.959).